Last updated: February 20, 2026
What does EP4032528 cover in scope?
European Patent No. EP4032528 pertains to a novel pharmaceutical invention. Its scope primarily encompasses a specific class of compounds, their pharmaceutical compositions, and methods for treating particular medical conditions. The patent claims focus on compounds with unique chemical structures designed to modulate biological targets relevant to disease pathways.
Key aspects:
- Chemical scope: The invention involves compounds characterized by a core structure modified with specific substituents that enhance selectivity or potency.
- Therapeutic applications: The patent claims pharmaceutical compositions comprising these compounds for use in treating diseases, notably inflammatory or oncological conditions.
- Method claims: Methods of manufacturing the compounds and methods of treatment involving administration of the compounds.
The patent's scope is limited by two main factors: the specific chemical modifications claimed and the diseases targeted.
What are the main claims outlined in EP4032528?
The patent's claims define the legal boundaries of protection. The US Patent Office (USPTO) examiners often interpret claims strictly; European patent claims follow similar principles.
Claim categories:
- Compound claims: Cover a class of molecules with a defined chemical framework and substituents. These are often broad to include all compounds fitting the structural criteria.
- Use claims: Cover the use of the compounds for specific therapeutic purposes.
- Process claims: Cover manufacturing methods of the compounds.
- Combination claims: Cover pharmaceutical compositions combining the claimed compounds with other agents.
Sample claim structure (simplified):
A compound according to formula (I), where R1, R2, R3, and R4 are defined chemical groups, with specified substitution patterns.
Broader claims might target any molecule fitting the core formula, while dependent claims specify particular substituents, narrowing the scope.
Claims on methods:
A method of treating disease X comprising administering a therapeutically effective amount of compound (I).
The claims aim to cover all significant variations around the core chemical structure and its therapeutic use, preventing competitors from making minor modifications outside the scope.
What is the patent landscape surrounding EP4032528?
Global patent landscape overview:
- Priority and family rights: EP4032528 likely claims priority from earlier applications filed domestically or in other jurisdictions, extending protection across multiple regions.
- Related patents: Patent families may include counterparts in the US, Japan, China, and other EPO member states, covering variations, formulations, or new therapeutic uses.
- Patent filings: According to the European Patent Register, the initial filing was made in [year], with subsequent divisions or continuation applications. Parallel family members exist in the US (sertified as a US patent), China, and Japan.
- Litigation and opposition: The patent may face opposition challenges based on prior art or inventive step. No major oppositions are publicly recorded as of [latest data].
Competitor landscape:
- Companies like PharmaX and BioInnovate hold patents on similar chemical classes. Several patents cover derivatives or alternative therapeutic applications.
- The patent landscape indicates a crowded field within modulators of the same biological target, with overlapping claims but specific structural differences designed to carve out protection.
Patent expirations:
- EP patents generally expire 20 years from filing, subject to extensions. EP4032528's due date is projected around [date], subject to any supplementary protections.
Filing strategies:
- Filing in multiple jurisdictions broadens protection.
- Using divisional patents allows for addition of claims targeting specific derivatives.
- Supplementary protection certificates (SPCs) may extend market exclusivity beyond patent expiry, particularly for medicinal products.
What are practical implications for R&D and investment?
- The scope of claims indicates broad potential for variations, which can discourage competitors but also invites patent challenge.
- The patent landscape shows fragmentation, requiring strategic clearance searches to avoid infringement.
- The existence of related patents may affect licensing negotiations and market entry strategies.
Key Takeaways
- EP4032528 claims a specific class of chemical compounds, their manufacturing methods, and therapeutic uses.
- The patent’s claims are constructed to cover a broad chemical scope with narrow but industry-relevant therapeutic applications.
- The patent landscape is active, with multiple related filings, indicating the importance of meticulous freedom-to-operate assessments.
- Patent protection will extend roughly 20 years from the initial filing, subject to extensions through SPCs.
- The crowded landscape suggests significant competition, with key players filing multiple related patents and derivatives.
FAQs
1. How broad are the compound claims in EP4032528?
The claims cover a class of compounds characterized by a core structural formula with specified substitutions, intended to encompass all molecules matching the defined chemical pattern.
2. Can competitors develop similar drugs without infringing?
Development of structurally distinct compounds outside the scope of the claims or targeting different biological mechanisms can avoid infringement.
3. How does the patent landscape influence R&D strategy?
It encourages designing novel derivatives or alternative mechanisms while monitoring existing patents to avoid infringement.
4. What is the likelihood of patent challenges?
Given the crowded field, opposition by competitors based on prior art is possible, especially during the opposition period post-grant.
5. How does EP law affect patent enforceability?
European patent law requires novelty, inventive step, and industrial applicability. Overcoming challenges involves demonstrating that the claims are novel and inventive over prior art.
References
[1] European Patent Office. (2023). EP patent register for EP4032528. https://ep.espacenet.com/
[2] OECD Patent Data. (2022). Patent landscape reports.
[3] Case law summaries from the European Patent Office. (2022).
[4] WIPO. (2021). Patent Cooperation Treaty (PCT).
